Dissolution enhancement of raltegravir by hot melt extrusion technique

الملخص EN

The objective of the study to develop an amorphous solid dispersion for poorly soluble raltegravir by hot melt extrusion (HME) technique.

A novel solubility improving agent plasdone s630 was utilized.

The HME raltegravir was formulated into tablet by direct compression method.

The prepared tablets were assessed for all pre and post-compression parameters.

The drug- excipients interaction was examined by FTIR and DSC.

All formulas displayed complying with pharmacopoeial measures.

The study reveals that formula prepared by utilizing drug and plasdone S630 at 1:1.5 proportion and span 20 at concentration about 30mg (trail-6) has given highest dissolution rate than contrasted with various formulas of raltegravir.